Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial". Bleeding Thromb Vascul Biol. 2025;4(2). doi:10.4081/btvb.2025.179